NYU Langone Medical Center and Lutheran Medical Center to create integrated healthcare network

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NYU LANGONE Medical Center and Lutheran Medical Center will create a clinically integrated health care provider network for the New York metropolitan area.

This agreement creates a formal health system between the two organizations that extends NYU Langone’s presence in Brooklyn, while bolstering Lutheran’s access to NYU Langone’s vast offering of medical and surgical specialties. Regulatory approval for the combination and new health system entity are expected to be completed in 2015.

NYU Langone has multiple ambulatory sites throughout the region, in addition to its main Manhattan hospital campuses, and Lutheran, in collaboration with its affiliated health center, Lutheran Family Health Centers, operates an expansive network of ambulatory practices in four boroughs of New York.

“We have been working closely with Lutheran over the last several months to assess whether a partnership would benefit each of our institutions, the Brooklyn community and, most importantly, the patients and families who turn to us for help,” said Robert Grossman, dean and CEO of NYU Langone.

This affiliation agreement allows both institutions to respond to this changing landscape and stabilize health care delivery in Brooklyn. This will be accomplished by:

The affiliation will create a fully integrated delivery system in Brooklyn using Lutheran’s existing primary care network, develop a system-wide IT infrastructure, and will focus on key initiatives including maternal and child health, cancer services, cardiac and vascular services, and physician network development.

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login